Methodological challenges for living systematic reviews conducted during the COVID-19 pandemic: A concept paper by Iannizzi, C, Dorando, E, Burns, J, Weibel, S, Dooley, C, Wakeford, H, Estcourt, LJ, Skoetz, N, Piechotta, V

Living systematic reviews in a context of rapidly emerging diseases: challenges and lessons learned by Iannizzi, C, Dorando, E, Burns, J, Weibel, S, Dooley, C, Wakeford, H, Estcourt, LJ, Skoetz, N, Piechotta, V

Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first‐line treatment in adults with transplant‐ineligible multiple myeloma: A network meta‐analysis... by Piechotta, V, Jakob, T, Langer, P, Monsef, I, Scheid, C, Estcourt, L, Ocheni, S, Theurich, S, Kuhr, K, Scheckel, B, Adams, A, Skoetz, N

Convalescent plasma and hyperimmune immunoglobulin to prevent infection with SARS‐CoV‐2 by Valk, SJ, Piechotta, V, Kimber, C, Chai, KL, Monsef, I, Doree, C, Wood, EM, Lamikanra, AA, Roberts, DJ, McQuilten, Z, So-Osman, C, Estcourt, LJ, Skoetz, N

Hyperimmune immunoglobulin for people with COVID-19 by Kimber, C, Valk, SJ, Chai, KL, Piechotta, V, Iannizzi, C, Monsef, I, Wood, EM, Lamikanra, AA, Roberts, DJ, McQuilten, Z, So-Osman, C, Estcourt, LJ, Skoetz, N

Convalescent plasma or hyperimmune immunoglobulin for people with COVID‐19: a living systematic review by Piechotta, V, Iannizzi, C, Chai, KL, Valk, SJ, Kimber, C, Dorando, E, Monsef, I, Wood, EM, Lamikanra, AA, Roberts, DJ, McQuilten, Z, So-Osman, C, Estcourt, LJ, Skoetz, N

SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19 by Hirsch, C, Valk, SJ, Piechotta, V, Chai, KL, Estcourt, LJ, Monsef, I, Salomon, S, Tomlinson, E, Popp, M, Wood, EM, So-Osman, C, Roberts, DJ, McQuilten, Z, Skoetz, N, Kreuzberger, N

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 by Kreuzberger, N, Hirsch, C, Chai, KL, Tomlinson, E, Khosravi, Z, Popp, M, Neidhardt, M, Piechotta, V, Salomon, S, Valk, SJ, Monsef, I, Schmaderer, C, Wood, EM, So-Osman, C, Roberts, DJ, McQuilten, Z, Estcourt, LJ, Skoetz, N